Keywords
Cancer pathogenesis
Reactive oxygen/nitrogen species
Pro-inflammatory signaling pathways
Immune cell infiltration
Therapeutic implications
Submitted : 2024-06-01
Accepted : 2024-06-16
Published : 2024-07-01
Abstract
Chronic inflammatory diseases as a cause of global cancer trend? Chronic inflammation is a condition where inflammation has persisted for a long time and is not relieved on its own as it promotes tumor growth. This paper aims to outline some of the vital biological processes and signaling pathways involved in the association of cancer with chronic inflammation. One of the functions of this relationship is to create reactive oxygen species (ROS) and nitric oxides (NOs) involved in mediating signal pathways that activate inflammation, the migration of immune cells, and cytokines. Recent studies imply that chronic inflammation may be involved in the pathogenesis of cancer conditions like hepatitis-B virus-induced hepatocellular carcinoma and colon carcinoma arising in the context of inflammatory bowel disease. These processes are necessary for creating therapies for both prevention and diseases. Consequently, the discovery and production of new drugs that can prevent cancer prevalence and increase survival rate within a population depends on correctly identifying the molecular mechanisms that connect disease to inflammation. The study collects the current research and lays out the foundation for future research that may use these conclusions to improve further the diagnosis and treatment of cancer and cancer prevention strategies.
References
Khandia R and Munjal A, 2020, Interplay between Inflammation and Cancer. Advances in Protein Chemistry and Structural Biology, 2020(119): 199–245.
Qian S, Golubnitschaja O, Zhan X, 2019, Chronic Inflammation: Key Player and Biomarker: Set to Predict and Prevent Cancer Development and Progression Based on Individualized Patient Profiles. Epma Journal, 10(4): 365–381.
Aggarwal V, Tuli HS, Varol A, et al., 2019, Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules, 9(11): 735.
Nigam M, Mishra AP, Deb VK, et al., 2023, Evaluation of the Association of Chronic Inflammation and Cancer: Insights and Implications. Biomedicine and Pharmacotherapy, 2023(164): 115015.
Krajka-Kuzniak V, Belka M, Papierska K, 2024, Targeting STAT3 and NF-KB Signaling Pathways in Cancer Prevention and Treatment: The Role of Chalcones. Cancers, 16(6): 1092.
Shah SC, Itzkowitz SH, 2022, Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology, 162(3): 715–730.
Kanda T, Goto T, Hirotsu Y, et al., 2019, Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. International Journal of Molecular Sciences, 20(6): 1358.
Parris BA, O ‘Farrell HE, Fong KM, et al., 2019, Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer: Common Pathways for Pathogenesis. Journal of Thoracic Disease, 11(Suppl 17): S2155.
Deshmukh SK, Srivastava SK, Poosarla T, et al., 2019, Inflammation, Immunosuppressive Microenvironment and Breast Cancer: Opportunities for Cancer Prevention and Therapy. Annals of Translational Medicine, 7(20): 593.
Sokolova O, Naumann M, 2019, Crosstalk between DNA Damage and Inflammation in the Multiple Steps of Gastric Carcinogenesis. Molecular Mechanisms of Inflammation: Induction, Resolution and Escape by Helicobacter pylori, 2019, 107–137.
Sharif PM, Jabbari P, Razi S, et al., 2020, Importance of TNF-alpha and its Alterations in the Development of Cancers. Cytokine, 2020(130): 155066.
Hirano T, 2021, IL-6 in Inflammation, Autoimmunity and Cancer. International Immunology, 33(3): 127–148.
Wu T, Yang W, Sun A, et al., 2022, The Role of CXC Chemokines in Cancer Progression. Cancers, 15(1): 167.
Zhang T, Ma C, Zhang Z, et al., 2021, NF-KB Signaling in Inflammation and Cancer. MedComm, 2(4): 618–653.
Harrington BS, Annunziata CM, 2019, NF-KB Signaling in Ovarian Cancer. Cancers, 11(8): 1182.
Wang H Q, Man Q W, Huo F Y, et al., 2022, STAT3 Pathway in Cancers: Past, Present, and Future. MedComm, 3(2): 124.
Brooks AJ, Putoczki T, 2020, JAK-STAT Signalling Pathway in Cancer. Cancers, 12(7): 1971.
Braicu C, Buse M, Busuioc C, et al., 2019, A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers, 11(10): 1618.
Guo YJ, Pan WW, Liu SB, et al., 2020, ERK/MAPK Signalling Pathway and Tumorigenesis. Experimental and Therapeutic Medicine, 19(3): 1997–2007.
Nakamura H, Takada K, 2021, Reactive Oxygen Species in Cancer: Current Findings and Future Directions. Cancer Science, 112(10): 3945–3952.
Perillo B, Donato MD, Pezone A, et al., 2020, ROS in Cancer Therapy: The Bright Side of the Moon. Experimental & Molecular Medicine, 52(2): 192–203.
Ilango S, Paital B, Jayachandran P, et al., 2020, Epigenetic Alterations in Cancer. Frontiers in Bioscience-Landmark, 25(6): 1058–1109.
Neophytou CM, Panagi M, Stylianopoulos T, et al., 2021, The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities. Cancers, 13(9): 2053.
Aguilar-Cazares D, Chavez-Dominguez R, Carlos-Reyes A, et al., 2019, Contribution of Angiogenesis to Inflammation and Cancer. Frontiers in Oncology, 2019(9): 1399.
Nadeem M S, Kumar V, Al-Abbasi F A, et al., 2020, Risk of Colorectal Cancer in Inflammatory Bowel Diseases. Seminars in Cancer Biology, 2020(64): 51–60.
Rajamaki K, Taira A, Katainen R, et al., 2021, Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-associated Colorectal Cancer. Gastroenterology, 161(2): 592–607.
Wangensteen KJ, Chang KM, 2021, Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology, 2021(73): 27–37.
Kim J, Wang TC, 2021, Helicobacter pylori and Gastric Cancer. Gastrointestinal Endoscopy Clinics, 31(3): 451–465.
Pereira-Marques J, Ferreira RM, Pinto-Ribeiro I, et al., 2019, Helicobacter pylori Infection, the Gastric Microbiome and Gastric Cancer. Helicobacter pylori in Human Diseases: Advances in Microbiology, Infectious Diseases and Public Health, 2019(11): 195–210.
Kandikattu HK, Venkateshaiah SU, Mishra A, 2020, Chronic Pancreatitis and the Development of Pancreatic Cancer. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 20(8): 1182–1210.
Grady WM, Yu M, Markowitz SD, et al., 2020, Barrett’s Esophagus and Esophageal Adenocarcinoma Biomarkers. Cancer Epidemiology, Biomarkers & Prevention, 29(12): 2486–2494.
Greten FR, Grivennikov SI, 2019, Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity, 51(1): 27–41.
Keum N, Giovannucci E, 2019, Global Burden of Colorectal Cancer: Emerging Trends, Risk Factors and Prevention Strategies. Nature Reviews Gastroenterology & Hepatology, 16(12): 713–732.
Loomans-Kropp HA, Umar A, 2019, Cancer Prevention and Screening: The Next Step in the Era of Precision Medicine. NPJ Precision Oncology, 3(1): 3.
Amjad MT, Chidharla A, Kasi A, 2020, Cancer Chemotherapy, in StatPearls [Internet], StatPearls Publishing, Treasure Island (FL).
Mohan G, Hamna A, Jijo A J, et al., 2019, Recent Advances in Radiotherapy and its Associated Side Effects in Cancer: A Review. The Journal of Basic and Applied Zoology, 80(1): 1–10.
Zheng Y, Yang H, Wang H, et al., 2019, Fluorescence-guided Surgery in Cancer Treatment: Current Status and Future Perspectives. Annals of Translational Medicine, 7(Suppl 1): S6.
Schirrmacher V, 2019, From Chemotherapy to Biological Therapy: A Review of Novel Concepts to Reduce the Side Effects of Systemic Cancer Treatment. International Journal of Oncology, 54(2): 407–419.
Baumgart DC, Misery L, Naeyaert S, et al., 2019, Biological Therapies in Immune-mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Frontiers in Pharmacology, 2019(10): 279.
Mishra AK, Ali A, Dutta S, et al., 2022, Emerging Trends in Immunotherapy for Cancer. Diseases, 10(3): 60.
Gambardella V, Tarazona N, Cejalvo JM, et al., 2020, Personalized Medicine: Recent Progress in Cancer Therapy. Cancers, 12(4): 1009.
Tsimberidou AM, Fountzilas E, Nikanjam M, et al., 2020, Review of Precision Cancer Medicine: Evolution of the Treatment Paradigm. Cancer Treatment Reviews, 2020(86): 102019.
Hou J, Karin M, Sun B, 2021, Targeting Cancer-promoting Inflammation: Have Anti-Inflammatory Therapies Come of Age? Nature Reviews Clinical Oncology, 18(5): 261–279.
Hrdy J, Sukenikova L, Petraskova P, et al., 2020, Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes: A Potential Alternative to Current Anti-Inflammatory Drugs? Microorganisms, 8(5): 621.
Helmink BA, Khan MAW, Hermann A, et al., 2019, The Microbiome, Cancer, and Cancer Therapy. Nature Medicine, 25(3): 377–388.